🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Syncom Formulations (India) Limited SYNCOMF NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.syncomformulations.com
Company Profile ↓
₹13.90
-26.57% 1Y
Mkt Cap₹1,306.60 Cr
P/E17.16
P/B3.40
52W High₹19.02
52W Low₹10.30
Book Value₹4.41
EPS (TTM)₹0.81

Company Overview

Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, dry syrups and suspensions, creams, gel, ORS, jelly, gynae, inhalers, opthal, ortho, and pediatrics formulations in dosage forms. It also provides life care, evolve, and the right nutrition products under the Cratus brand. In addition, the company offers its pharmaceutical formulation products in various dosage forms, such as tablets, capsules, ointments, injections, liquids orals, and effervescent. Syncom Formulations (India) Limited was incorporated in 1988 and is based in Indore, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 18.4%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 23.8%.

Consistent Profit Growth

Net profit has compounded at 56.2% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 30.0% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 17.2, below the sector median of 40.0.

Healthy Margins

Maintains a net profit margin of 15.6%.

Recent Developments

  • Mar 2026 Revenue of ₹489.17 Cr (+5.2% YoY); net profit ₹76.44 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +5.2%, earnings +54.6%.
  • 5-Year Trend Long-term compounding — revenue CAGR 30.0%, profit CAGR 56.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:30.03%
1 Year:5.20%

Compounded Profit Growth

5 Years:56.16%
1 Year:54.62%

Stock Price Performance

1 Year:-26.57%
6 Months:+5.86%
3 Months:-0.36%
1 Month:-3.94%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 41% of range
₹10.30 ₹19.02
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • Golden Cross3d ago
  • RSI (14)45.88 · Neutral
Price Performance
1M-3.94%
3M-0.36%
6M+5.86%
1Y-26.57%
Valuation vs Sector

P/E of 17.16 is below the sector median of 39.97 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Healthy ROCE of 23.8%.
  • Compounding revenue at 30.0% over 5 years.
  • Profit CAGR of 56.2% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading 26.9% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
17.16
Industry PE
39.97
Forward P/E est.
11.10
PEG Ratio
-
Book Value
₹4.41
Price to Book
3.40
P/S
2.68
EV/EBITDA
15.71
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
30.03%
Profit 5Y
56.16%
Revenue (YoY)
5.20%
Earnings (YoY)
54.62%

Profitability & Returns

ROCE
23.78%
ROE
18.42%
ROA
14.32%
Profit Margin
15.63%
Op Margin
14.49%
Gross Margin
41.89%
EPS (Latest Qtr)
₹0.27
EPS (TTM)
₹0.81

Balance Sheet & Liquidity

Debt/Equity
0.36
Quick Ratio
2.58
Current Ratio
3.18
Debt
₹1.47 Cr
Total Assets
₹533.85 Cr
Current Assets
₹330.37 Cr
Working Capital
₹226.64 Cr

Ownership

Promoter Holding
50.57%
Chg in Prom Hold
-0.00%
FII / Inst Holding
0.12%
Chg in FII Hold
-0.01%

Financial Snapshot

Enterprise Value
₹1,306.60 Cr
Total Revenue (TTM)
₹489.17 Cr
EBITDA
₹108.81 Cr
Free Cash Flow
₹46.41 Cr
Operating Cash Flow
₹58.08 Cr
Shares Outstanding
₹94.00 Cr
Gross Margin
41.89%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 SYNCOMF Syncom Formulations (India) Limited NSEPHARMA 13.90 17.16 ₹1,306.60 Cr 0.00% 23.78% 18.42% 30.03% 56.16%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 61.00 Cr60.00 Cr64.00 Cr65.00 Cr75.00 Cr87.00 Cr102.00 Cr-148.88 Cr116.90 Cr121.72 Cr115.14 Cr135.41 Cr
Cost of Revenue --------100.37 Cr69.17 Cr70.75 Cr61.04 Cr83.31 Cr
Gross Profit --------48.51 Cr47.73 Cr50.96 Cr54.10 Cr52.10 Cr
Operating Expenses 55.00 Cr53.00 Cr57.00 Cr58.00 Cr65.00 Cr77.00 Cr90.00 Cr-32.05 Cr33.27 Cr33.91 Cr34.25 Cr32.57 Cr
Operating Income 5.00 Cr5.00 Cr5.00 Cr6.00 Cr8.00 Cr9.00 Cr11.00 Cr-16.47 Cr14.47 Cr17.05 Cr19.85 Cr19.53 Cr
EBITDA 6.00 Cr6.00 Cr6.00 Cr7.00 Cr9.00 Cr10.00 Cr12.00 Cr-24.70 Cr21.88 Cr23.65 Cr26.71 Cr36.56 Cr
Interest Expense 1.00 Cr1.00 Cr1.00 Cr1.00 Cr1.00 Cr00-11.68 L25.08 L26.49 L26.34 L37.59 L
Pretax Income 10.00 Cr6.00 Cr8.00 Cr9.00 Cr10.00 Cr10.00 Cr15.00 Cr-23.30 Cr20.29 Cr22.04 Cr25.09 Cr33.70 Cr
Tax Provision 1.80 Cr1.68 Cr1.84 Cr2.25 Cr2.60 Cr2.40 Cr3.75 Cr-5.61 Cr4.54 Cr5.44 Cr6.18 Cr8.53 Cr
Net Income 8.00 Cr4.00 Cr7.00 Cr7.00 Cr7.00 Cr8.00 Cr11.00 Cr-17.69 Cr15.75 Cr16.60 Cr18.91 Cr25.17 Cr
Diluted EPS 0.090.050.070.070.080.080.12-0.190.210.180.230.27

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 115.00 Cr151.00 Cr173.00 Cr184.00 Cr185.00 Cr-222.49 Cr259.24 Cr465.01 Cr489.17 Cr
Cost of Revenue ------149.85 Cr165.00 Cr307.34 Cr284.27 Cr
Gross Profit ------72.64 Cr94.24 Cr157.68 Cr204.90 Cr
Operating Expenses 104.00 Cr135.00 Cr155.00 Cr167.00 Cr168.00 Cr-56.18 Cr69.07 Cr108.74 Cr134.00 Cr
Operating Income 8.00 Cr13.00 Cr15.00 Cr14.00 Cr14.00 Cr-16.45 Cr25.17 Cr48.94 Cr70.90 Cr
EBITDA 11.00 Cr16.00 Cr18.00 Cr17.00 Cr17.00 Cr-34.30 Cr43.03 Cr71.57 Cr108.81 Cr
Interest Expense 1.00 Cr0000-3.19 Cr4.36 Cr86.49 L1.16 Cr
Pretax Income 8.00 Cr14.00 Cr16.00 Cr16.00 Cr16.00 Cr-26.57 Cr33.95 Cr65.51 Cr101.12 Cr
Tax Provision 2.64 Cr4.62 Cr6.08 Cr5.76 Cr5.44 Cr-6.50 Cr8.64 Cr16.08 Cr24.68 Cr
Net Income 6.00 Cr9.00 Cr10.00 Cr10.00 Cr11.00 Cr-20.07 Cr25.31 Cr49.43 Cr76.44 Cr
Diluted EPS 0.070.120.130.130.13-0.220.270.530.81

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 123.00 Cr140.00 Cr138.00 Cr175.00 Cr180.00 Cr-377.83 Cr404.66 Cr413.28 Cr533.85 Cr
Current Assets ------181.69 Cr274.78 Cr269.97 Cr330.37 Cr
Cash & Equivalents ------75.81 L63.29 Cr65.85 L5.15 Cr
Inventory ------21.20 Cr21.08 Cr41.33 Cr62.88 Cr
Receivables ------75.51 Cr103.30 Cr107.55 Cr110.50 Cr
Total Liabilities ------121.82 Cr116.52 Cr71.12 Cr118.86 Cr
Current Liabilities ------113.16 Cr106.52 Cr59.31 Cr103.73 Cr
Long Term Debt -----0----
Total Debt 2.00 Cr3.00 Cr6.00 Cr6.00 Cr12.00 Cr-83.18 Cr72.49 Cr4.58 Cr1.47 Cr
Total Equity 87.00 Cr95.00 Cr100.00 Cr109.00 Cr117.00 Cr-256.01 Cr288.14 Cr342.16 Cr414.99 Cr
Shares Outstanding ------94.00 Cr94.00 Cr94.00 Cr94.00 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 6.00 Cr7.00 Cr024.00 Cr14.00 Cr-10.53 Cr-5.96 Cr23.44 Cr58.08 Cr
Investing Cash Flow -0-4.00 Cr1.00 Cr-23.00 Cr-18.00 Cr--44.95 Cr83.02 Cr-18.20 Cr-50.62 Cr
Financing Cash Flow -6.00 Cr-1.00 Cr1.00 Cr-2.00 Cr5.00 Cr-35.00 Cr-14.56 Cr-67.90 Cr-3.02 Cr
Capital Expenditure -3.00 Cr-3.00 Cr-3.00 Cr-3.00 Cr-12.00 Cr--20.63 Cr-8.14 Cr-9.96 Cr-11.67 Cr
Free Cash Flow 3.00 Cr4.00 Cr-3.00 Cr21.00 Cr2.00 Cr--10.11 Cr-14.09 Cr13.48 Cr46.41 Cr
Net Change in Cash -1.00 Cr2.00 Cr2.00 Cr-1.00 Cr1.00 Cr-57.80 L62.50 Cr-62.67 Cr4.44 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ------32.6%36.4%33.9%41.9%
Operating Margin % 7.0%8.6%8.7%7.6%7.6%-7.4%9.7%10.5%14.5%
Net Margin % 5.2%6.0%5.8%5.4%5.9%-9.0%9.8%10.6%15.6%
ROE % 6.9%9.5%10.0%9.2%9.4%-7.8%8.8%14.4%18.4%
ROCE % ------6.2%8.4%13.8%16.5%

Shareholding Pattern

Insiders
50.57%
Institutions
0.12%
Public Float
0.25%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SYNCOMF

Google News ue, 26 May 2026

Here's Why Syncom Formulations (India) (NSE:SYNCOMF) Has Caught The Eye Of Investors - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi-gFBVV95cUxNbGFLZllwVkNnd18zdmNFZ1BHS0hJQkJUdGNtajc2aFVnRVpuV2lUckpFaE5UZG1BOEdkWFBVNHRhbnhkRXE2bklaOWJ6UU8ta3dFWmRYWVJ4YXFYdkplVmE5ZTZOeVpwZmdPeS1QMnozZEk2alhFXzZNdkhmMUxSSmR4XzZCWkx2U2ZsRj…

Google News Fri, 18 Nov 2022

SYNCOMF Stock Price and Chart — NSE:SYNCOMF - TradingView

<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE45NW1jdFJEbUExNWowemxUTVZsSEhuVGJucGhGYVJ1eDZtSnNEOWRmUTNEMnJOWl9UV2I4ZGVzcm1WVy10WExqZEpXZTh0WTZVRHl0VjdjcVJHdVlQ?oc=5" target="_blank">SYNCOMF Stock Price and Chart — NSE:SYNCOMF…

Google News Sat, 24 Jun 2023

Technical Analysis of Syncom Formulation (India) Ltd. (NSE:SYNCOMF) - TradingView

<a href="https://news.google.com/rss/articles/CBMia0FVX3lxTFBQMWRhYVVZOTVTQkRiZFNPVGNJS0xESUlxalBPX3B0emM1OG5PeFpBRmNIaVFSc2dIUV9xNmY4TE4tbnRCaEs5cXZ1eWtlaDFpdEFrVkgwcDdQMmM5TTV3VG4yUzU4RUR6bHhN?oc=5" target="_blank">Technical Analysis of S…

Google News Fri, 25 Mar 2022

Syncom Formulations (India) Ltd. Share Price Today | Syncom Form Live NSE/BSE - Value Research

<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxPMkVoN0I5cGgza0lMMjJTYWZOQk9oYjYzdW1TUlFIOGRsd0hhWWh6c3g0cUgwSFdSN3lYdFdRWFRScDZDcEV6bGRkdkN3NkhBeUkwYXVoV3JrVTJJTkpKZ2ZzSEdmLTJla3lJNW9lYzZXNmdxcmQyYmhFQXlzQlFEek9adVh4Zw?oc=5" t…

Google News Fri, 18 Jul 2025

Syncom Formulation (India) Ltd. Share Price Live Today - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxNNmxLRE9ZMWFyYWZ2TDJnb0FBNTlSVjE5QnR1TW83M05VOTZVVGNaWnBsellIdGswaGxpb19RMVZjU1ZFeHMtOHNSVWZwQzJobkxLSE9kOEZ3RUthVVAwbUI4YWlIVVd6Yi14eHRDU3JSSFg2dk9rX3plTnI0SlFUNVM2aG9pVWRLR1pkWm…

Google News Fri, 18 Aug 2017

INDSWFTLAB Stock Price and Chart — NSE:INDSWFTLAB - TradingView

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTFBXa3NaQWZwc2hWMWJnMHZkSmxuRmNfUjRab3hOcGs0b0xxMVBQMU1rTUFjUjRhUG8wVkhHQkxIZXNBM2dBc1cxcDRGakxHQld2dEp0NWc1ekhHek5LcEU0aw?oc=5" target="_blank">INDSWFTLAB Stock Price and Chart — NS…

SYNCOMF — Frequently Asked Questions

What is the current share price of Syncom Formulations (India) Limited (SYNCOMF)?

As of 2026-07-15 09:52 IST, Syncom Formulations (India) Limited (SYNCOMF) trades at ₹13.90 on NSE. Its 52-week range is ₹10.30 to ₹19.02.

What is the market capitalisation of SYNCOMF?

Syncom Formulations (India) Limited (SYNCOMF) has a market capitalisation of ₹1,306.60 Cr on NSE.

What is the P/E ratio of SYNCOMF?

SYNCOMF trades at a trailing price-to-earnings (P/E) ratio of 17.16. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 3.40.

What is the return on equity (ROE) of SYNCOMF?

SYNCOMF has a return on equity (ROE) of 18.42%. Its return on capital employed (ROCE) is 23.78%.

Is SYNCOMF a good stock to buy?

This page provides a data-driven analysis of Syncom Formulations (India) Limited (SYNCOMF), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space